Sankar Subramanian
Known title: Senior VP, Product DevelopmentCIK: 0001856744
Sankar Subramanian's purchase track record
Sankar Subramanian has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/26/2022 | NAUT | $30K | -15.3% | +28.1% | +8.8% |
| 9/15/2022 | NAUT | $163K | -29.0% | +1.8% | +1.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| NAUT | ▲ Buy | Open Market | 5,000 | $10K | 9/27/2022 | View on chart |
| NAUT | ▲ Buy | Open Market | 10,000 | $20K | 9/26/2022 | View on chart |
| NAUT | ▲ Buy | Open Market | 35,000 | $75K | 9/16/2022 | View on chart |
| NAUT | ▲ Buy | Open Market | 40,000 | $88K | 9/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Roth Capital initiates coverage on NAUT with $3.50 target
Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.
Roth Capital initiates coverage on NAUT with $3.50 target. Roth Capital began tracking Nautilus Biotechnology with a Buy rating and a price target of $3.50. This new analyst note adds to the current consensus, where the average target from two analysts is $4.00. The stock is currently trading within its 52-week range of $0.72 to $4.31.